These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 29658055)

  • 1. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
    Kondoh C; Kadowaki S; Komori A; Narita Y; Taniguchi H; Ura T; Ando M; Muro K
    Gastric Cancer; 2018 Nov; 21(6):1050-1057. PubMed ID: 29658055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.
    Tsuji K; Yasui H; Onozawa Y; Boku N; Doyama H; Fukutomi A; Yamazaki K; Machida N; Todaka A; Taniguchi H; Tsushima T; Yokota T
    Jpn J Clin Oncol; 2012 Aug; 42(8):686-90. PubMed ID: 22693245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer.
    Cho YH; Kim SY; Hong Lee M; Yoo MW; Bang HY; Lee KY; Yoon SY
    Gastric Cancer; 2012 Oct; 15(4):389-95. PubMed ID: 22237658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens.
    Kaya AO; Coskun U; Gumus M; Dane F; Ozkan M; Isıkdogan A; Alkis N; Buyukberber S; Yumuk F; Budakoglu B; Demirci U; Berk V; Bilici A; Inal A; Arpacı E; Benekli M;
    J Chemother; 2012 Aug; 24(4):217-20. PubMed ID: 23040686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
    Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
    Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.
    Anter AH; Abdel-Latif RM
    Med Oncol; 2013 Mar; 30(1):451. PubMed ID: 23307258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study.
    Kim JH; Lee SC; Oh SY; Song SY; Lee N; Nam EM; Lee S; Hwang IG; Lee HR; Lee KT; Bae SB; Kim HJ; Jang JS; Lim DH; Lee HW; Kang SY; Kang JH
    Cancer Commun (Lond); 2018 Jun; 38(1):32. PubMed ID: 29866170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
    Kang EJ; Im SA; Oh DY; Han SW; Kim JS; Choi IS; Kim JW; Kim YJ; Kim JH; Kim TY; Lee JS; Bang YJ; Lee KW
    Gastric Cancer; 2013 Oct; 16(4):581-9. PubMed ID: 23266882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin combination chemotherapy in patients with recurrent or metastatic gastric cancer.
    Lan YQ; Wu RP; Huang XB; Wang XL; Zhong DT; Huang CY; Song JT
    Tumori; 2018; 104(1):22-29. PubMed ID: 28777427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFOX (oxaliplatin and 5 fluorouracil/leucovorin) in patients with untreated metastatic gastric adenocarcinoma Phase II study.
    Mohammad HA; Magdy FM; Mahmoud OM
    Indian J Cancer; 2011; 48(4):460-5. PubMed ID: 22293261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.
    Kim ST; Kang WK; Kang JH; Park KW; Lee J; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Park YS; Im YH; Park K
    Br J Cancer; 2005 May; 92(10):1850-4. PubMed ID: 15870718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
    Soularue É; Cohen R; Tournigand C; Zaanan A; Louvet C; Bachet JB; Hentic O; Samalin E; Chibaudel B; de Gramont A; André T;
    Bull Cancer; 2015 Apr; 102(4):324-31. PubMed ID: 25744576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
    Kim SH; Lee GW; Go SI; Cho SH; Kim HJ; Kim HG; Kang JH
    Am J Clin Oncol; 2010 Dec; 33(6):572-6. PubMed ID: 20042971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; Jäger E;
    J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as first-line treatment for patients with advanced gastric cancer.
    Lin RB; Fan NF; Guo ZQ; Wang XJ; Liu J; Chen L
    J Chemother; 2008 Dec; 20(6):744-8. PubMed ID: 19129074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.
    Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Lee SS; Lee JS; Kang YK
    Am J Clin Oncol; 2008 Apr; 31(2):151-6. PubMed ID: 18391599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified FOLFOX6) with advanced gastric cancer patients having a good or poor performance status.
    Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Esenkaya A; Uzunoglu S; Cicin I
    Asian Pac J Cancer Prev; 2015; 16(6):2355-9. PubMed ID: 25824764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
    Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
    Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies.
    Mitani S; Kadowaki S; Komori A; Kondoh C; Oze I; Kato K; Masuishi T; Honda K; Narita Y; Taniguchi H; Ando M; Tanaka T; Tajika M; Muro K
    Adv Ther; 2020 Jun; 37(6):2853-2864. PubMed ID: 32378071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.